دورية أكاديمية
Outcomes of Critically Ill Children With Acute Lymphoblastic Leukemia and Cytokine Release Syndrome Due to Chimeric Antigen Receptor T Cell Therapy: US, Multicenter PICU, Cohort Database Study.
| العنوان: | Outcomes of Critically Ill Children With Acute Lymphoblastic Leukemia and Cytokine Release Syndrome Due to Chimeric Antigen Receptor T Cell Therapy: US, Multicenter PICU, Cohort Database Study. |
|---|---|
| المؤلفون: | Logan GE; Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO., Miller K; Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO., Kohler ME; Department of Pediatrics, Section of Hematology and Oncology, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO., Loi M; Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO.; Department of Pediatrics, Section of Hematology and Oncology, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO., Maddux AB; Department of Pediatrics, Section of Critical Care Medicine, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO. |
| المصدر: | Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies [Pediatr Crit Care Med] 2022 Dec 01; Vol. 23 (12), pp. e595-e600. Date of Electronic Publication: 2022 Oct 04. |
| نوع المنشور: | Multicenter Study; Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 100954653 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-7535 (Print) Linking ISSN: 15297535 NLM ISO Abbreviation: Pediatr Crit Care Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Baltimore, MD : Lippincott Williams & Wilkins, c2000- |
| مواضيع طبية MeSH: | Receptors, Chimeric Antigen* , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy, Child ; Humans ; Infant ; Critical Illness/therapy ; Intensive Care Units, Pediatric ; Retrospective Studies ; Cytokine Release Syndrome ; Cohort Studies ; Cell- and Tissue-Based Therapy |
| مستخلص: | Objectives: Cytokine release syndrome (CRS) is a potentially lethal toxicity associated with chimeric antigen receptor T cell therapy for pediatric acute lymphoblastic leukemia (ALL). Outcomes after critical illness due to severe CRS are poorly described. Our aim was to characterize critical illness outcomes across a multicenter cohort of PICU patients with ALL and CRS. Design: Multicenter retrospective cohort study. Setting: Twenty-one PICUs contributing data to Virtual Pediatric Systems, LLC (January 2020-December 2021). Patients: PICU patients with ALL or unclassified leukemia and CRS. Interventions: None. Measurements and Main Results: We identified 55 patients; 34 (62%) were 12 years or older, 48 (87%) were admitted from a hospital inpatient ward, and 23 (42%) received advanced organ failure support or monitoring. Fifty-one survived to PICU discharge (93%) including 19 of 23 (83%) who received advanced organ failure support or monitoring defined as receipt of noninvasive or invasive ventilation, cardiopulmonary resuscitation, extracorporeal membrane oxygenation, continuous renal replacement therapy, or placement of a tracheostomy, arterial catheter, hemodialysis catheter, or intracranial catheter. Twelve patients (22%) received invasive ventilation, nine of whom survived to PICU discharge. Two of four patients who received continuous renal replacement therapy and one of three patients who required cardiopulmonary resuscitation survived to PICU discharge. Lengths of PICU stay were median 3.0 days (interquartile range, 1.4-7.8 d) among PICU survivors, 7.8 (5.4-11.1) among those receiving advanced organ failure support or monitoring, and 7.2 days (interquartile range, 2.9-14.7 d) among nonsurvivors. Of the 51 patients who survived to PICU discharge, 48 (94%) survived the hospitalization. Conclusions: PICU patients with CRS frequently received a high level of support, and the majority survived their PICU stay and hospitalization. Additional multicenter investigations of severe CRS are necessary to inform evidence-based practice. Competing Interests: Drs. Kohler and Maddux received support for article research from the National Institutes of Health; they disclosed the off-label products use of tocilizumab, glucocorticoids, siltuximab, and anakinra. Dr. Maddux’s institution received funding from the National Institute of Child Health and Human Development (K23HD096018) and the Francis Family Foundation/Parker B. Francis Fellowship. The remaining authors have disclosed that they do not have any potential conflicts of interest. (Copyright © 2022 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.) |
| References: | Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al.: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 2015; 385:517–528. Gardner RA, Finney O, Annesley C, et al.: Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 2017; 129:3322–3331. Pasquini MC, Hu ZH, Curran K, et al.: Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv 2020; 4:5414–5424. Maude SL, Frey N, Shaw PA, et al.: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507–1517. Maude SL, Laetsch TW, Buechner J, et al.: Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378:439–448. Laetsch TW, Yanik GA, Boyer MW, et al.: An owner’s manual for CD19 “CAR”-T cell therapy in managing pediatric and young adult B-cell acute lymphoblastic leukemia. Blood Rev 2021; 50:100848. Curran KJ, Margossian SP, Kernan NA, et al.: Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood 2019; 134:2361–2368. Lee DW, Santomasso BD, Locke FL, et al.: ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25:625–638. Ragoonanan D, Khazal SJ, Abdel-Azim H, et al.: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 2021; 18:435–453. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al.: Cytokine release syndrome. J Immunother Cancer 2018; 6:56. Mahadeo KM, Khazal SJ, Abdel-Azim H, et al.; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 2019; 16:45–63. Shalabi H, Sachdev V, Kulshreshtha A, et al.: Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J Immunother Cancer 2020; 8:e001159. Levine JE, Grupp SA, Pulsipher MA, et al.: Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. J Immunother Cancer 2021; 9:e002287. Wetzel RC, Sachedeva R, Rice TB: Are all ICUs the same? Paediatr Anaesth 2011; 21:787–793. Pollack MM, Patel KM, Ruttimann UE: PRISM III: An updated Pediatric Risk of Mortality score. Crit Care Med 1996; 24:743–752. Straney L, Clements A, Parslow RC, et al.; ANZICS Paediatric Study Group and the Paediatric Intensive Care Audit Network: Paediatric Index of Mortality 3: An updated model for predicting mortality in pediatric intensive care*. Pediatr Crit Care Med 2013; 14:673–681. Pollack MM, Holubkov R, Funai T, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network: Pediatric intensive care outcomes: Development of new morbidities during pediatric critical care. Pediatr Crit Care Med 2014; 15:821–827. Ghafoor S, Fan K, Di Nardo M, et al.: Extracorporeal membrane oxygenation candidacy in pediatric patients treated with hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy: An international survey. Front Oncol 2021; 11:798236. Zinter MS, McArthur J, Duncan C, et al.; Hematopoietic Cell Transplant and Cancer Immunotherapy Subgroup of the PALISI Network: Candidacy for extracorporeal life support in children after hematopoietic cell transplantation: A position paper from the Pediatric Acute Lung Injury and Sepsis Investigators Network’s hematopoietic cell transplant and cancer immunotherapy subgroup. Pediatr Crit Care Med 2022; 23:205–213. Moynihan KM, Jansen M, Siegel BD, et al.: Extracorporeal membrane oxygenation candidacy decisions: An argument for a process-based longitudinal approach. Pediatr Crit Care Med 2022; 23:e434–e439. Frey NV, Porter DL: Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016; 2016:567–572. |
| معلومات مُعتمدة: | K12 CA086913 United States CA NCI NIH HHS; K23 HD096018 United States HD NICHD NIH HHS |
| المشرفين على المادة: | 0 (Receptors, Chimeric Antigen) |
| تواريخ الأحداث: | Date Created: 20221004 Date Completed: 20221205 Latest Revision: 20231202 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC9722524 |
| DOI: | 10.1097/PCC.0000000000003079 |
| PMID: | 36194016 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1529-7535 |
|---|---|
| DOI: | 10.1097/PCC.0000000000003079 |